2012 | 4 | 631-639
Article title

Mechanizm tworzenia i diagnostyka płynu opłucnowego

Title variants
Languages of publication
  • Droszcz W, i wsp. Choroby opłucnej. Warszawa: Wydawnictwo Lekarskie PZWL; 1997.
  • Payne KD, Owens D. Differentiating between benign and malignant pleural effusion. In: Bouros D, ed. Pleural disease.New York: Marcel Dekker; 2004: 253–261.
  • . Miller LG, Kazemi H. Choroby płuc. Warszawa: Wydawnictwo Lekarskie PZWL; 1988.
  • Lynch TJ. Management of malignant pleural effusions. Chest 1993; 103: 385–389.
  • . Sahn SA. Malignant pleural effusion. In: Bouros D, ed. Pleural disease. New York: Marcel Dekker; 2004: 411–438.
  • McLaughlin JS, Krasna MJ. Parapneumonic empyema. In: Shields TW, et al., ed. General thoracic surgery. Philadelphia:Lippincott Williams and Wilkins; 2005: 819–832.
  • American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000; 162:1987–2001.
  • . Antony VB, Loddenkemper R, Astoul P, et al. Management of malignant pleural effusions. Eur Respir J 2001; 18: 402–419.
  • Grymiński J. Choroby opłucnej. W: Krakówka P, Rowińska-Zakrzewska E, red. Choroby układu oddechowego.Warszawa: PZWL; 1993: 445–459.
  • Traill ZC, Davies RJ, Gleeson FV. Thoracic computed tomography in patients with suspected malignant pleural effusions.Clin Radiol 2001; 56: 193–196.
  • Arenas-Jimenez J, Alonso-Charterina S, Sanchez-Paya J, et al. Evaluation of CT findings for diagnosis of pleural effusions.Eur Radiol 2000; 10: 681–690.
  • Lee YC, Chen W, Shih TF. Computed tomography in the evaluation of pleural dissemination in lung cancer. J Formos Med Assoc 1990; 89: 1063–1066.
  • Gavelli G, Giampalma E, Celletti F. CT and MRI role in lung cancer staging. In: Second International Congress of Thorax Surgery; 1998 June 24–26, Bologna, Italy. Editrice Compositori; 1998: 45–47.
  • . Hierholzer J, Liangping L, Bittner RC, et al. MRI and CT in the differential diagnosis of pleural disease. Chest 2000118: 604–609.;
  • Erasmus JJ, McAdams HP, Rossi SE, et al. FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR 2000; 175: 245–249.
  • Ferlin G, Rubello F, Chierichetti F. PET role in lung cancer staging. In: Second International Congress of Thorax Surgery;1998 June 24–26; Bologna, Italy. Editrice Compositori; 1998: 49–50.
  • Health and Public Policy Committee, American, College of Physicians. Diagnostic thoracocentesis and pleural biopsy in pleural effusions. An Int Med 1985; 103: 799–802.
  • . Kacprzak G, Gabryś K. Optymalizacja leczenia chirurgicznego chłonkotoków opłucnowych. Pol Przegl Chir 2000; 72:381–386.
  • Droszcz W. Badania mikrobiologiczne, immunologiczne, biochemiczne i alergologiczne. W: Droszcz W, Kowalski J,Pawlicka L, i wsp., red. Diagnostyka chorób układu oddechowego. Warszawa: Wydawnictwo Lekarskie PZWL; 1987:207–211.
  • Light RW. Useful tests on the pleural fluid in the management of patients with pleural effusions. Curr Opin Pulm Med 1999; 5: 245–249.
  • Joseph J, Badrinath P, Basran GS, et al. Is the pleural fluid transudate or exudate? A revisit of the diagnostic criteria. Thorax 2001; 56: 867–870.
  • Grogan DR, Irwin RS, Channick R, et al. Complications associated with thoracocentesis. Arch Intern Med 1990; 150: 873–877.
  • Little AG. Thoracoscopy: current status. Curr Opin Pulm Med 1996; 2: 315–319.
  • Jabłonka S. Miejsce videotorakoskopii w chirurgii klatki piersiowej. W: 56 Zjazd Towarzystwa chirurgów Polskich; 1993 wrzesień 8–11. Lublin. Polska. Lublin: POL-ILKO; 1993: 426.
  • Lewis RJ, Caccavale RJ, Sisler GE. Imaged thoracoscopic lung biopsy. Chest 1992; 102: 60–62.
  • Loddenkemper R, Boutin C. Thoracoscopy: present diagnostic and therapeutic indications. Eur Respiro J 1993; 6: 1544–1555.
  • Weatherford DA, Stephenson JE, Taylor SM, et al. Thoracoscopy versus thoracotomy: indications and advantages. Am Surg 1995; 61: 83–86.
  • Yap KP, Tan NC. Video-assisted thoracoscopy: role in the management of intrathoracic pathology. Ann Acad Med Singapore 1999; 28(6): 816–818.
  • . Stella F, Ansaloni L, Bini A, et al. VATS value in the diagnosis, staging and pallative treatment of malignant pleural mesothelioma.In: Second International Congress of Thorax Surgery; 1998 June 24–26; Bologna, Italy. Editrice Compositori;1998: 325–330.
  • Porcel JM, Vives M, Esquerda A, et al. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004; 126:1757–1763.
  • . Davidson B. Malignant effusions: from diagnosis to biology. Diagn Cytopathol 2004; 31: 246–254.
  • . Kremer R, Best LA, Savulescu D, et al. Pleural fluid analysis of lung cancer vs benign inflammatory disease patients. Br J Cancer. 2010; 102(7): 1180–1184.
  • . Bielsa S, Esquerda A, Salud A, et al. High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions. Eur J Intern Med 2009; 20(4): 383–386.
  • Suzuki H, Hirashima T, Kobayashi M, et al. Cytokeratin 19 fragment/carcinoembryonic antigen ratio in pleural effusion is a useful marker for detecting malignant pleural mesothelioma. Anticancer Res 2010; 30(10): 4343–4346.
  • Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Am J Surg Pathol 2009; 33(11):1673–1682.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.